New radioactive drug targets Hard-to-Treat prostate cancer

NCT ID NCT05603559

Recruiting now Disease control Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing two new radioactive drugs, 177Lu-P17-087 and 177Lu-P17-088, in 30 people with metastatic castration-resistant prostate cancer that has stopped responding to other treatments. The study first checks how the drug spreads in the body and its safety, then tests higher doses to find the best amount. The goal is to see if this approach can safely deliver radiation directly to cancer cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 177Lu-P17-087 and 177Lu-P17-088 (radioactive drugs)
What this could lead to: If it works, this could point toward a new treatment option for advanced prostate cancer that has stopped responding to standard therapies.
What could go wrong: This is a very early, small trial (30 people) focused on safety and dosing. It is not yet designed to prove effectiveness, and the treatment may cause side effects like low blood counts or liver/kidney issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Peking Union Medical College Hospital
RECRUITING

Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.